Insulin and glycolysis dependency of cardioprotection by nicotinamide riboside

Y. Xiao,Q. Wang,H. Zhang,R. Nederlof,D. Bakker,B. A. Siadari,M. W. Wesselink,B. Preckel,N. C. Weber,M. W. Hollmann,B. V. Schomakers,M. van Weeghel,C. J. Zuurbier

DOI: https://doi.org/10.1007/s00395-024-01042-4

IF: 12.416

2024-03-27

Basic Research in Cardiology

Abstract:Decreased nicotinamide adenine dinucleotide (NAD + ) levels contribute to various pathologies such as ageing, diabetes, heart failure and ischemia–reperfusion injury (IRI). Nicotinamide riboside (NR) has emerged as a promising therapeutic NAD + precursor due to efficient NAD + elevation and was recently shown to be the only agent able to reduce cardiac IRI in models employing clinically relevant anesthesia. However, through which metabolic pathway(s) NR mediates IRI protection remains unknown. Furthermore, the influence of insulin, a known modulator of cardioprotective efficacy, on the protective effects of NR has not been investigated. Here, we used the isolated mouse heart allowing cardiac metabolic control to investigate: (1) whether NR can protect the isolated heart against IRI, (2) the metabolic pathways underlying NR-mediated protection, and (3) whether insulin abrogates NR protection. NR protection against cardiac IRI and effects on metabolic pathways employing metabolomics for determination of changes in metabolic intermediates, and 13 C-glucose fluxomics for determination of metabolic pathway activities (glycolysis, pentose phosphate pathway (PPP) and mitochondrial/tricarboxylic acid cycle (TCA cycle) activities), were examined in isolated C57BL/6N mouse hearts perfused with either (a) glucose + fatty acids (FA) ("mild glycolysis group"), (b) lactate + pyruvate + FA ("no glycolysis group"), or (c) glucose + FA + insulin ("high glycolysis group"). NR increased cardiac NAD + in all three metabolic groups. In glucose + FA perfused hearts, NR reduced IR injury, increased glycolytic intermediate phosphoenolpyruvate (PEP), TCA intermediate succinate and PPP intermediates ribose-5P (R5P) / sedoheptulose-7P (S7P), and was associated with activated glycolysis, without changes in TCA cycle or PPP activities. In the "no glycolysis" hearts, NR protection was lost, whereas NR still increased S7P. In the insulin hearts, glycolysis was largely accelerated, and NR protection abrogated. NR still increased PPP intermediates, with now high 13 C-labeling of S7P, but NR was unable to increase metabolic pathway activities, including glycolysis. Protection by NR against IRI is only present in hearts with low glycolysis, and is associated with activation of glycolysis. When activation of glycolysis was prevented, through either examining "no glycolysis" hearts or "high glycolysis" hearts, NR protection was abolished. The data suggest that NR's acute cardioprotective effects are mediated through glycolysis activation and are lost in the presence of insulin because of already elevated glycolysis.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The key problems that this paper attempts to solve include:

1. **Can NR protect the heart from ischemia - reperfusion injury (IRI)?**
- Using an isolated mouse heart model, the researchers explored whether nicotinamide riboside (NR) could protect the heart from ischemia - reperfusion injury (IRI). By comparing the experimental results under different metabolic conditions, they found that NR could significantly reduce IRI under low - glycolytic conditions.

2. **What are the metabolic pathways of NR - mediated cardioprotection?**
- To reveal the cardioprotective mechanism of NR, the researchers analyzed the influence of NR on different metabolic pathways. They used metabolomics and fluxomics methods to detect the changes in glycolysis, the pentose phosphate pathway (PPP), and the tricarboxylic acid cycle (TCA cycle). The results showed that NR activated glycolysis under low - glycolytic conditions and increased the levels of NAD+ and the concentrations of other metabolic intermediates.

3. **The influence of insulin on the protective effect of NR**
- Insulin is a known regulator of cardioprotective effects. The researchers further studied whether the protective effect of NR would be affected in the presence of insulin. Experiments showed that under high - glycolytic conditions (i.e., in the presence of insulin), the protective effect of NR disappeared. This indicates that the cardioprotective effect of NR depends on a low - glycolytic state, and the presence of insulin will offset the effect of NR due to the already elevated glycolytic level.

### Specific problem analysis

- **The cardioprotective effect of NR**:
- Under low - glycolytic conditions (glucose + fatty acid), NR significantly reduced the myocardial infarction area, decreased the release of lactate dehydrogenase (LDH), and improved the recovery of post - ischemic cardiac function.

- **Metabolic pathway analysis**:
- NR increased the NAD+ content in the heart and activated the glycolytic pathway. Specifically:
- Phosphoenolpyruvate (PEP) increased.
- Intermediate products of the pentose phosphate pathway (PPP) such as ribose - 5 - phosphate (R5P) and sedoheptulose - 7 - phosphate (S7P) increased.
- Intermediate products of the tricarboxylic acid cycle (TCA cycle) such as succinate increased.

- **The influence of insulin**:
- Under high - glycolytic conditions (glucose + fatty acid + insulin), the protective effect of NR disappeared. This is because insulin accelerates glycolysis, making it impossible for NR to further increase glycolytic activity or enhance its protective effect.

In summary, this study aims to reveal the cardioprotective effect of NR and its mechanism under different metabolic conditions, and pays special attention to the influence of insulin on this protective effect. The study shows that the cardioprotective effect of NR depends on a low - glycolytic state, and this protective effect will be weakened or disappear under high - glycolytic conditions (such as in the presence of insulin).